OTC Markets · Biotechnology · USD

Reviva Pharmaceuticals Holdings, Inc. (RVPH) Stock Analysis

Reviva Pharmaceuticals Holdings, Inc. (RVPH) is a Biotechnology stock listed on OTC Markets and quoted in US Dollar.

RVPH

$0.53

−$0.01 (−1.85%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare RVPH with… →

RVPH Key Statistics

As of Sep 4, 2026

Trading

Open: $0.53
Previous Close: $0.54
Day's Range: 0.51–0.56
52-Week Range: 0.26–17.20
Volume: 23.52K
Beta: 0.50

Valuation

Market Cap: $6.95M
P/E Ratio: unprofitable
EPS (ttm): −1.03

Financials (FY)

Revenue (FY): $0.00
Net Income (FY): −$19.86M
Profit margin: 0.00%
Shares Outstanding: 13.11M
1-Year Return: −94.07%

Dividend and dates

Earnings Date: November 12, 2026estimated
Avg Volume: 48.16K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

RVPH Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

+8.23%−66.95%+47.06%+21.18%−64.85%−84.59%−90.50%

2020*202120222023202420252026*

Year	Return
2026 (partial year)	−90.50%
2025	−84.59%
2024	−64.85%
2023	+21.18%
2022	+47.06%
2021	−66.95%
2020 (partial year)	+8.23%

As of September 4, 2026.

RVPH Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$0.00	−$19.86M	—
2024	$0.00	−$29.92M	—
2023	$0.00	−$39.26M	—
2022	$0.00	−$28.26M	—

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$0.00	—	−$20.20M	−$19.86M	—
2024	$0.00	—	−$30.80M	−$29.92M	—
2023	$0.00	—	−$39.50M	−$39.26M	—
2022	$0.00	—	−$28.23M	−$28.26M	—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

RVPH Valuation vs Biotechnology Median

Median of 656 stocks

Metric	RVPH	Biotechnology median	vs median
Profit margin	0.00%	0.00%	0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

Reviva Pharmaceuticals Holdings, Inc. (RVPH) carries a market capitalisation of $6.95M. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 14 employees.

Over the past 52 weeks the price has ranged from $0.26 to $17.20. The most recent close on file for RVPH is $0.53, dated September 4, 2026. That is −$0.01 (−1.85%) against the previous close. The latest close sits 102.29% above that 52-week low.

Financial Health

In fiscal 2025, Reviva Pharmaceuticals Holdings, Inc. reported revenue of $0.00. The same year closed with a net loss of $19.86M. The reported profit margin is 0%. Earnings per share on a trailing basis come to −1.03.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

The trailing one-year price return is −94.07%. Measured over 5 years, that is −63.91% a year compounded. Beta against the wider market is reported at 0.5. Annualized volatility over the trailing 5 years is 131.81%.

Growth & Income

The record shows no dividend for RVPH.

The strongest complete calendar year on file is 2022 at +47.06%; the weakest is 2025 at −84.59%. Of the 5 complete calendar years on file, 2 finished higher. So far in 2026 the price is −90.50%.

Peer Comparison

Reviva Pharmaceuticals Holdings, Inc. (RVPH) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Reviva Pharmaceuticals Holdings, Inc.	RVPH	$6.95M	—
Vertex Pharmaceuticals Incorporated	VRTX	$138.42B	32.5
Regeneron Pharmaceuticals, Inc.	REGN	$85.22B	20.5
argenx SE	ARGX	$64.25B	40.1

The Biotechnology industry average P/E ratio is 12.6x. Reviva Pharmaceuticals Holdings, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

ARGX

argenx SE

$64.25B

MRNA

Moderna, Inc.

$58.11B

RVMD

Revolution Medicines, Inc.

$45.01B

ONC

BeOne Medicines AG

$40.53B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About Reviva Pharmaceuticals Holdings, Inc.

Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of neuropsychiatric indications, such as schizophrenia, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis. It also engages in the clinical development for respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis. In addition, the company is in preclinical development for the treatment of psoriasis; and RP1208 for the treatment of depression and obesity. The company was founded in 2018 and is headquartered in Cupertino, California.

Visit website →